What changed in this filing

/stocks — the workspaceLOADING

Item 5. Other Information

2022-08-15 compared with 2022-05-16 · 43 added, 63 removed, 58 unchanged (65% of the section changed)

9 unchanged sentences

Form of Warrant (7)

Form of Investor Warrant dated May 16, 2022(32)

Collaboration Agreement dated December 29, 2015 (8)

18 unchanged sentences

investors (22)

Amended and Restated Amercian BriVision (Holding) Corporation 2016 Equity Incentive (26)

Amended and Restated American BriVision (Holding) Corporation 2016 Equity Incentive (26)

Form of Securities Purchase Agreement (27)

5 unchanged sentences

Amendment to the Collaboration Agreement dated December 29, 2015

Clinical Development Service Agreement with Rgene (portions of the exhibit have been omitted because they (i) are not material and (ii) is the type of information that the registrant treats as private or confidential.)(31)

Convertible Note issued to Regene, dated June 16, 2022(31)

Form of Securities Purchase Agreement dated May 12, 2022 (32)

Certifications pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.+

11 unchanged sentences

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

accordance with SEC Release 33-8238, Exhibits 32.1 and 32.2 are being furnished and not filed.

(1) Incorporated

by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on February 16, 2016.

(2) Incorporated

by reference to Exhibit 3.01 to the Company’s Form SB-2 filed on June 28, 2002

(3) Incorporated

by reference to Exhibit 3.02 to the Company’s Form SB-2, filed on June 28, 2002

(4) Incorporated

by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K, filed on March 28, 2016.

(5) Incorporated

by reference to Exhibit 3.4 to the Company’s Form S-1, filed on September 13, 2016.

(6) Incorporated

by reference to Exhibit 3.1 to the Company’s Form 8-K, filed on April 7, 2020

(7) Incorporated

by reference to Exhibit 4.1 the Company’s Current Report on Form 8-K, filed on April 24, 2020

(8) Incorporated

by reference to Exhibit 10.2 the Company’s Current Report on Form 8-K, filed on February 16, 2016.

(9) Incorporated

by reference to Exhibit 99.1 to the Company’s Current Report on Form 8-K, filed on June 9, 2016.

Incorporated by reference

to Exhibit 10.3 to the Company’s Annual Report on Form 10-K, filed on January 12, 2017.

Incorporated by reference

to Exhibit 99.1 to the Company’s Current Report on Form 8-K, filed on February 22, 2017.

Incorporated by reference

to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on July 24, 2017.

Incorporated by reference

to Exhibit 99.1 to the Company’s Current Report on Form 8-K, filed on May 30, 2017.

Incorporated by reference

to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on September 20, 2017.

Incorporated by reference

to Exhibit 10.3 to the Company’s Current Report on Form 8-K, filed on September 20, 2017.

Incorporated by reference

to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on February 1, 2019.

Incorporated by reference

to Exhibit 10.2 to the Company’s Current Report on Form 8-K, filed on February 1, 2019.

Incorporated by reference

to Exhibit 10.3 to the Company’s Current Report on Form 8-K, filed on February 1, 2019.

Incorporated by reference

to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on April 24, 2020.

Incorporated by reference

to Exhibit 10.3 to the Company’s Current Report on Form 8-K, filed April 14, 2020.

Incorporated by reference

to Exhibit 10.15 to the Company’s Annual Report on Form 10-K, filed May 15, 2020.

Incorporated by reference

to Exhibit 10.16 to the Company’s Annual Report on Form 10-K, filed May 15, 2020

Incorporated by reference

to Exhibit 14.1 to the Company’s Amendment No.1 to Form S-1, filed on November 14, 2016.

Incorporated by reference

to 21.1 to the Company’s Form S-1, filed on September 13, 2016.

Incorporated by reference

to Exhibit 10.9 to the Company’s Annual Report on Form 10-K, filed May 15, 2020.

Incorporated by reference

to Exhibit 10.17 to the Company’s Annual Report on Form 10-K, filed March 16, 2021.

Incorporated by reference

to the Current Report on Form 8-K filed on November 5, 2020.

Incorporated by reference

to the Current Report on Form 8-K filed on June 8, 2021.

Incorporated by reference

to the Quarterly Report on Form 10-Q filed on May 10, 2021.

Incorporated by reference

to the Current Report on Form 8-K filed on October 8, 2021.

In accordance with SEC Release 33-8238, Exhibits 32.1 and 32.2 are being furnished and not filed.

Filed herewith

Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on February 16, 2016.

Incorporated by reference to Exhibit 3.01 to the Company’s Form SB-2 filed on June 28, 2002

Incorporated by reference to Exhibit 3.02 to the Company’s Form SB-2, filed on June 28, 2002

Incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K, filed on March 28, 2016.

Incorporated by reference to Exhibit 3.4 to the Company’s Form S-1, filed on September 13, 2016.

Incorporated by reference to Exhibit 3.1 to the Company’s Form 8-K, filed on April 7, 2020

Incorporated by reference to Exhibit 4.1 the Company’s Current Report on Form 8-K, filed on April 24, 2020

Incorporated by reference to Exhibit 10.2 the Company’s Current Report on Form 8-K, filed on February 16, 2016.

Incorporated by reference to Exhibit 99.1 to the Company’s Current Report on Form 8-K, filed on June 9, 2016.

Incorporated by reference to Exhibit 10.3 to the Company’s Annual Report on Form 10-K, filed on January 12, 2017.

Incorporated by reference to Exhibit 99.1 to the Company’s Current Report on Form 8-K, filed on February 22, 2017.

Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on July 24, 2017.

Incorporated by reference to Exhibit 99.1 to the Company’s Current Report on Form 8-K, filed on May 30, 2017.

Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on September 20, 2017.

Incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K, filed on September 20, 2017.

Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on February 1, 2019.

Incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K, filed on February 1, 2019.

Incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K, filed on February 1, 2019.

Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on April 24, 2020.

Incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K, filed April 14, 2020.

Incorporated by reference to Exhibit 10.15 to the Company’s Annual Report on Form 10-K, filed May 15, 2020.

Incorporated by reference to Exhibit 10.16 to the Company’s Annual Report on Form 10-K, filed May 15, 2020

Incorporated by reference to Exhibit 14.1 to the Company’s Amendment No.1 to Form S-1, filed on November 14, 2016.

Incorporated by reference to 21.1 to the Company’s Form S-1, filed on September 13, 2016.

Incorporated by reference to Exhibit 10.9 to the Company’s Annual Report on Form 10-K, filed May 15, 2020.

Incorporated by reference to Exhibit 10.17 to the Company’s Annual Report on Form 10-K, filed March 16, 2021.

by reference to the Current Report on Form 8-K filed on November 5, 2020.

by reference to the Current Report on Form 8-K filed on June 8, 2021.

by reference to the Quarterly Report on Form 10-Q filed on May 10, 2021.

by reference to the Current Report on Form 8-K filed on October 8, 2021.

by reference to the Current Report on Form 8-K filed on June 21, 2022.

by reference to the Current Report on Form 8-K filed on May 12, 2022.

Pursuant to the requirements of the Securities

1 unchanged sentence

ABVC BioPharma, Inc.

August 15, 2022

/s/ Howard Doong

Chief Executive Officer

1 unchanged sentence

ABVC BioPharma, Inc.

/s/ Chihliang

August 15, 2022

/s/ Chihliang An

Chief Financial Officer

1 unchanged sentence

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 5. Other Information